Scynexis Inc
$ 0.62
6.20%
29 Dec - close price
- Market Cap 24,637,700 USD
- Current Price $ 0.62
- High / Low $ 0.64 / 0.59
- Stock P/E N/A
- Book Value 0.87
- EPS -0.51
- Next Earning Report 2026-04-01
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -0.53 %
- 52 Week High 1.49
- 52 Week Low 0.56
About
Scynexis Inc. is a biotechnology company headquartered in Jersey City, New Jersey, focused on advancing treatment options for invasive fungal infections, with a particular emphasis on challenging yeast infections. The company’s flagship product, BREXAFEMME®, represents a significant advancement as the first oral therapy specifically approved for vulvovaginal candidiasis, reflecting its commitment to innovation in antifungal treatments. Scynexis is further strengthened by a robust pipeline of candidates designed to meet the urgent needs within the infectious disease landscape, positioning the company for potential growth and a substantial foothold in the ever-evolving antifungal sector.
Analyst Target Price
$3.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-13 | 2025-05-06 | 2025-03-26 | 2024-11-11 | 2024-08-08 | 2024-05-08 | 2024-02-07 | 2023-11-13 | 2023-08-14 | 2023-05-10 | 2023-03-31 |
| Reported EPS | -0.17 | -0.14 | -0.11 | -0.09 | -0.06 | -0.3 | 0.01 | -0.39 | -0.04 | 2.46 | -0.71 | -0.37 |
| Estimated EPS | -0.2 | -0.2 | -0.2 | -0.02 | -0.07 | -0.2 | -0.2 | -0.2 | -0.15 | 1.55 | -0.28 | -0.44 |
| Surprise | 0.03 | 0.06 | 0.09 | -0.07 | 0.01 | -0.1 | 0.21 | -0.19 | 0.11 | 0.91 | -0.43 | 0.07 |
| Surprise Percentage | 15% | 30% | 45% | -350% | 14.2857% | -50% | 105% | -95% | 73.3333% | 58.7097% | -153.5714% | 15.9091% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-01 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.1267 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SCYX
2025-12-22 13:16:00
SCYNEXIS, Inc. has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement for its common stock, with a new deadline of June 15, 2026. This extension was given because SCYNEXIS meets other listing criteria and plans to address the deficiency, potentially through a reverse stock split. The company is focusing on advancing its strategic objectives, including completing a Phase 1 study for an intravenous formulation of SCY-247 and aiming for Phase 2 proof-of-concept data for oral SCY-247 in invasive candidiasis.
2025-12-22 13:09:51
SCYNEXIS, Inc. (NASDAQ: SCYX) has received a 180-calendar-day extension from Nasdaq to regain compliance with its minimum bid price requirement. The company now has until June 15, 2026, to maintain a closing bid price of at least $1.00 per share for ten consecutive business days. SCYNEXIS plans to advance its strategic objectives which include a Phase 1 study for an IV formulation of SCY-247 and Phase 2 data for the oral formulation of SCY-247 for invasive candidiasis infections.
2025-12-22 13:09:51
Biotechnology company Scynexis Inc. (NASDAQ:SCYX) has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement, needing its stock to maintain at least $1.00 for ten consecutive business days by June 15, 2026. Despite its current stock price of $0.63 and a 48.18% year-to-date decline, InvestingPro analysis suggests the company is undervalued and holds more cash than debt. Scynexis is actively developing SCY-247 for drug-resistant infections and plans to complete Phase 1 and generate Phase 2 data for intravenous and oral formulations, respectively.
2025-12-22 08:00:00
SCYNEXIS, Inc. (NASDAQ: SCYX) has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, pushing the deadline to June 15, 2026. The company plans to address this deficiency, potentially through a reverse stock split, while continuing to advance its strategic objectives, including a Phase 1 study for SCY-247 and generating Phase 2 data for the oral formulation of SCY-247 for invasive candidiasis infections. SCYNEXIS remains committed to full compliance with all Nasdaq listing requirements.
2025-12-22 08:00:00
SCYNEXIS, Inc. has received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, giving the company until June 15, 2026. This extension allows SCYNEXIS to continue advancing its strategic objectives, including a Phase 1 study for an IV formulation and Phase 2 data for an oral formulation of SCY-247, an investigational antifungal. The company remains committed to full compliance with Nasdaq listing requirements.
2025-11-24 05:00:33
Scynexis Inc. has completed the transfer of the Brexafemme New Drug Application to GSK. As a result, Scynexis is set to receive up to $145.5 million in annual net sales milestones in addition to royalties from GSK.
